The end of Alzheimer's disease - From biochemical pharmacology to ecopsychosociology: A personal perspective

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 677-681

  Whitehouse, Peter J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Psychosocial

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL RESEARCH; DIFFUSE LEWY BODY DISEASE; ENVIRONMENTAL FACTOR; FRONTOTEMPORAL DEMENTIA; HEALTH ECONOMICS; HUMAN; MILD COGNITIVE IMPAIRMENT; MOLECULAR GENETICS; MULTIINFARCT DEMENTIA; OPTIMISM; POLICY; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY;

ALZHEIMER'S DISEASE; AMYLOID; DEMENTIA; PSYCHOSOCIAL;

AGING; ALZHEIMER DISEASE; HUMANS;

EID: 84897954564     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.11.017     Document Type: Review

References (50)

1. P. Whitehouse, and D. George The aesthetics of natural elderhood J Aging Humanit Arts 4 2010 292 301
2. P.J. Whitehouse, D.R. George, and S. D'Alton Describing the dying days of "AD" J Alzheimers Dis 24 1 2011 11 13
3. O. Burger, A. Baudischa, and J.W. Vaupela Human mortality improvement in evolutionary context Proc Natl Acad Sci U S A 109 2013 18210 18214
4. P. Whitehouse Taking brain health to a deeper and broader level Neuro Inst J 2010 17 22 [Spring issue]
5. C.J.L. Murray, T. Vos, R. Lozano, M. Naghavi, A.D. Flaxman, and C. Michaud et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2197 2223
6. J. Stein, T. Schettler, B. Rohrer, and M. Valenti Environmental threats to healthy aging with a closer look at Alzheimer's & Parkinson's disease. A Report by Greater Boston Physicians for Social Responsibility, Boston 2008 http://www.agehealthy.org/pdf/GBPSRSEHN-HealthyAging1017.pdf
7. J.P. Fyke, and P.M. Buzzanell The ethics of conscious capitalism: wicked problems in leading change and changing leaders Hum Relat 2013 10.1177/0018726713485306
8. D.R. George, and P.J. Whitehouse Marketplace of memory: what the brain fitness technology industry says about us and how we can do better Gerontologist 51 5 2011 590 596
9. P.W. Whitehouse, and D. George The art of personalized medicine - banking on stories for healthier cognitive aging Lancet 373 2009 1166 1167
10. P.J. Whitehouse, E. Bendezu, S. Fallcreek, and C. Whitehouse Intergenerational community schools: a new practice for a new time Educ Gerontol 26 8 2000 761 770 (Pubitemid 33223317)
11. D. George, C. Whitehouse, and P. Whitehouse A model of intergenerativity: how the intergenerational school is bringing the generations together to foster collective wisdom and community health J Intergenerat Relat 9 2011 389 404
12. D.R. George, and P.J. Whitehouse Intergenerational volunteering and quality of life for persons with mild-to-moderate dementia: results from a 5-month intervention study in the United States J Am Geriatr Soc 58 4 2010 796 797
13. R. Holliday The extreme arrogance of anti-aging medicine Biogerentology 10 2009 223 228
14. A.S. Kesselheim, R.M. Cook-Deegan, D.E. Winickoff, and M.M. Mello Gene patenting - the Supreme Court finally speaks NEJM 369 2013 869 875
15. J. LaMattina Devalued and distrusted: can the pharmaceutical industry restore its broken image? 2012 Wiley Hoboken
16. K. Outterson Punishing health care fraud - is the GSK settlement sufficient? N Engl J Med 367 2012 1082 1090
17. S.S. Hall c 2013 New York, October 20, 2013 http://nymag.com/news/ features/cancer-drugs-2013-10/#print
18. H.M. Kantarjian, T. Fojo, M. Mathisen, A. Leonard, and L.A. Zwelling Cancer drugs in the United States: Justum Pretium - The Just Price J Clin Oncol 31 2013 3600 3604
19. R.T. Bartus, R.L. Dearn III, B. Beer, and A.S. Lippa The cholinergic hypothesis of geriatric memory dysfunction Science 217 1982 408 414
20. Commission de la transparence Médicaments de la maladie d'Alzheimer: à éviter Drugs for AD: best avoided. No therapeutic advantage Prescrire Int 21 128 June 2012 150 [PMID 22822592]
21. S. D'Alton, and D.R. George Changing perspectives on AD: thinking outside the amyloid box J Alzheimers Dis: JAD 25 4 2011 571 581
22. D. Krstic, and I. Knusel The airbag problem - a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's disease Acta Neuropathol Commun 1 2013 62
23. E. Karran, M. Mercken, and B. DeStrooper The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat Rev Drug Disov 10 2011 698 712
24. J. Hope Daily pill that halts Alzheimer's is hailed as 'biggest breakthrough against disease for 100 years' 2008 Mail Online 29th July 2008 http://www.dailymail.co.uk/health/article-1039677
25. N. Chernin UTSW doctor says, 'I think we're going to cure Alzheimer's disease, and we're not far away from it' Dallas Morning News May 28, 2013 2013 http://www.dallasnews.com/lifestyles/health-and-fitness/health/ 20130527-utsw-doctor-says-i-think-were-going-to-cure-alzheimers-disease-and- were-not-far-away-from-it.ece
26. K. Mullane, and M. Williams Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
27. V.L. Villemagne, W.E. Klunk, C.A. Mathis, C.C. Rowe, D.J. Brooks, and B.T. Hyman et al. Aβ imaging: feasible, pertinent, and vital to progress in Alzheimer's disease Eur J Nucl Med Mol Imaging 39 2012 209 219
28. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
29. Committee of Medicare and Medicaid Services Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N) 2013 http://www.cms.gov/medicare-coverage-database/details/nca- decisionmemo.aspx?NCAId=265&utm-medium=email&utm-source=govdelivery
30. M.A. Smith, C.S. Atwood, J.A. Joseph, and G. Perry Predicting the failure of amyloid beta vaccine Lancet 359 9320 2002 1864 1865 (Pubitemid 34607072)
31. R.J. Castellani, H.-G. Lee, X. Zhu, A. Nunomura, G. Perry, and M.A. Smith Neuropathology of Alzheimer's disease: pathognomonic but not pathogenic Acta Neuropathol 111 2006 503 509 (Pubitemid 43778954)
32. R.J. Castellani, H.-G. Lee, X. Zhu, G. Perry, and M.A. Smith Alzheimer disease pathology as a host response J Neuropathol Exp Neurol 67 2008 523 531 (Pubitemid 351787079)
33. J. Hardy The relationship between amyloid and tau J Mol Neurosci 20 2003 203 206 (Pubitemid 36693824)
34. K. Luan, J.L. Rosales, and K.Y. Lee Viewpoint: crosstalks between neurofibrillary tangles and amyloid plaque formation Ageing Res Rev 12 2013 174 181
35. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
36. C. Brayne, K. Richardson, F.E. Matthews, J. Fleming, S. Hunter, and J.H. Xuereb et al. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study J Alzheimer's Dis 18 2009 645 658
37. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas et al. The diagnosis of dementia due to AD: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD Alzheimer's Demen 7 3 2011 263 269
38. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of AD: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD Alzheimer's Demen 7 2011 280 292
39. M.S. Albert, S.T. DeKosky, D.W. Dickson, B.B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to AD: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD Alzheimer's Demen 7 2011 270 279
40. B. Dubois, H. Feldman, C. Jacova, J. Cummings, S. DeKosky, and P. Barberger-Gateau et al. Revising the definition of AD: a new lexicon Lancet Neurol 9 2011 118 1127
41. D. Blazer Neurocognitive disorders in DSM-5 Am J Psychiatr 170 2013 585 587
42. D.R. George, P.J. Whitehouse, and J. Ballenger The evolving classification of dementia: placing the DSM-V in a meaningful historical and cultural context and pondering the future of "Alzheimer's" Cult Med Psychiatry 35 3 2011 417 435
43. D. de Jong, R. Jansen, W. Hoefnagels, M. Jellesma-Eggenkamp, and M. Verbeek et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial PLoS ONE 3 1 2008 e1475
44. D. Flood, G. Marek, and M. Williams Developing predictive CSF biomarkers - a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine Biochem Pharmacol 81 2011 1422 1434
45. D.C. Anderson, and K. Kodulka Biomarkers in pharmacology and drug discovery Biochem. Pharmacol. 2013 10.1016/j.bcp.2013.08.026 [in press]
46. D.R. George, S.H. Qualls, C.J. Camp, and P.J. Whitehouse Renovating Alzheimer's: 'constructive' reflections on the new clinical and research diagnostic guidelines Gerontologist 2012 2012 1 12
47. P.J. Whitehouse, and D.R. George Uncertain progress on the fuzzy boundaries of AD: reading between the guidelines J Alzheimers Dis 26 2011 1 5
48. P. Belluck New Drug Trial Seeks to Stop Alzheimer's Before It Starts. New York Times 2012 15 May 2012. http://www.nytimes.com/2012/05/16/health/research/ prevention-is-goal-of-alzheimers-drug-trial.html
49. Z. Corbyn New set of Alzheimer's trials focus on prevention Lancet 381 2012 614 615
50. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, and Y.T. Quiroz et al. Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381